Bharat Biotech is an Indian pharmaceutical company that makes Covaxin. Indian papers reported, based on the company’s announcement, that Hungarian authorities approved the Good Manufacturing Practice (GMP) certificate of the product. However, this does not mean that Covaxin will ever be used in Hungary.
According to portfolio.hu, the Hungarian authorities did not report the decision, but Indian papers unequivocally state it, based on a Twitter post of Bharat Biotech. In India, this type of vaccine is widely used for immunisation.
The vaccine contains an inactivated virus, and it showed 78 pc efficiency against the infection and 100 pc defence against severe disease.
However, the product’s use was controversial since Indian healthcare workers had received it before its testing period finished, and nobody knew, for example, the side effects. Furthermore, there were gossips that the vaccine was tested in the slums of the country, and those who received it did not know that they got an experimental product.
According to MTI,
no Covid patients died over the past 24 hours, while 72 new coronavirus infections were registered,
koronavirus.gov.hu said on Thursday. So far 5,636,894 people have received their first jab, while 5,475,471 have been fully vaccinated.
The number of active infections has declined to 28,816, while hospitals are treating 79 Covid patients, 11 of whom need respiratory assistance. There are 1,364 people in official quarantine, while 6,367,442 tests have been officially carried out.
Since the first outbreak, 809,803 infections have been registered,
while fatalities have risen to 30,032. 750,955 people have made a full recovery. So far, most infections have been registered in Budapest and Pest County, followed by the counties of Borsod-Abaúj-Zemplén, Győr-Moson-Sopron and Hajdú-Bihar.